CIS Biopharma AG recently presented an antibody-drug conjugate (ADC) targeting the L1 cell adhesion molecule (L1CAM/CD171) as a potential candidate for the treatment of advanced tumors.
Sutro Biopharma Inc. has outlined its next-generation antibody-drug conjugate (ADC) pipeline following recent IND clearance and initiation of phase I for its tissue factor-targeting ADC, STRO-004.
Acrivon Therapeutics Inc. has developed a new WEE1/PKMYT1 inhibitor, ACR-2316, to overcome the limitations observed with previous WEE1 and PKMYT1 inhibitors in the treatment of cancer.
Forx Therapeutics AG presented data on their PARG inhibitor – FORX-428 – for the treatment of cancer. FORX-428 is a highly potent, selective and orally bioavailable PARG inhibitor that showed strong and reversible binding to the catalytic domain of the human PARG enzyme.
Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized antibody-drug conjugates (ADCs) comprising a claudin 6 (CLDN6)-targeting antibody linked to cytotoxic drug through linker. They are described as potentially useful for the treatment of ovarian cancer.
Step Pharma is financed to move its pipeline-in-a-product strategy forward on a broad front, after raising a €38 million (US$44.2 million) series C. That will see three ongoing trials testing the company’s potentially first-in-class, orally available cytidine triphosphate synthase 1 inhibitor, dencatistat, through to phase II in T-cell and B-cell lymphoma, in an ovarian, endometrial and lung cancer study, and in essential thrombocythemia.
Beijing Chempion Biotechnology Co. Ltd. has synthesized antibody-drug conjugates comprising antibodies targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
